如何在双原发恶性肿瘤中确定治疗优先级：一例非霍奇金淋巴瘤合并乳腺癌患者的病例报告

How to prioritize treatment in dual malignancy: A case report of patient with non-Hodgkin lymphoma and breast cancer.

作者信息

Chomariyati Alvi, Diansyah Muhammad Noor, Amrita Putu Niken Ayu, Romadhon Pradana Zaky, Yudho Bintoro Siprianus Ugroseno, Ashariati Ami, Savitri Merlyna

机构信息

Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia.

Staff Member of Hematology and Medical Oncology Division, Department of Internal Medicine, Dr. Soetomo General Teaching Hospital, Surabaya, Indonesia.

出版信息

Ann Med Surg (Lond). 2022 Jul 31;81:104300. doi: 10.1016/j.amsu.2022.104300. eCollection 2022 Sep.

DOI:10.1016/j.amsu.2022.104300

PMID:36147133

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9486382/

Abstract

INTRODUCTION

Clinicians often encounter dilemma upon treating multiple primary malignancies.

CASE PRESENTATION

We report a case of a female patient, 72, complained of a lump under her left eye since January 2019. Patient was diagnosed with infiltrating ductal carcinoma grade III of the right breast in June 2018 with ER+, PR+, and HER2-, treated with hormonal treatment. Histopathology examination of the lump revealed Non Hodgkin Lymphoma (NHL), B cell type, high grade. Patients received rituximab, cyclophosphamide, epirubicin, vincristin, and prednisone (RHCOP) for 6 cycles to overcome lymphoma then received hormonal therapy afterwards.

CLINICAL DISCUSSION

According to earlier published case reports, it's advised to start hormonal therapy after RHCOP. The survival time was 21 months (5.1-114.7 months) with 5-year overall survival 29.

CONCLUSION

Unfortunately, we could not have a follow-up on the patient after finishing 6 cycles of RHCOP due to the COVID-19 pandemic situation.

摘要

引言

临床医生在治疗多种原发性恶性肿瘤时常常面临两难境地。

病例介绍

我们报告一例72岁女性患者，自2019年1月起主诉左眼下方有肿块。该患者于2018年6月被诊断为右乳腺浸润性导管癌III级，雌激素受体（ER）阳性、孕激素受体（PR）阳性、人表皮生长因子受体2（HER2）阴性，接受了激素治疗。对肿块进行组织病理学检查发现为B细胞型高级别非霍奇金淋巴瘤（NHL）。患者接受了6个周期的利妥昔单抗、环磷酰胺、表柔比星、长春新碱和泼尼松（RHCOP）方案治疗以控制淋巴瘤，之后接受了激素治疗。